These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19249227)

  • 21. Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational study.
    Moro-Sibilot D; Vergnenegre A; Smit EF; Toy E; Parente B; Schmitz S; Kraaij K; Visseren-Grul C; Soldatenkova V; Arellano J; Leteneux C
    Curr Med Res Opin; 2010 Nov; 26(11):2661-72. PubMed ID: 20942749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival improvement in thoracic cancer: progress from the last decade and beyond.
    Manegold C; Thatcher N
    Lung Cancer; 2007 Aug; 57 Suppl 2():S3-5. PubMed ID: 17686443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The actual place of anti-angiogenesis in non-small cell lung cancer].
    Mennecier B
    Rev Mal Respir; 2007 Oct; 24(8 Pt 2):6S198-205. PubMed ID: 18235414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival among patients with platinum resistant, locally advanced non-small cell lung cancer treated with platinum-based systemic therapy.
    d'Amato TA; Pettiford BL; Schuchert MJ; Parker R; Ricketts WA; Luketich JD; Landreneau RJ
    Ann Surg Oncol; 2009 Oct; 16(10):2848-55. PubMed ID: 19609620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
    Crawford J
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pemetrexed: new indication. Untreated non-small cell lung cancer: just another cytotoxic drug. No better than the gemcitabine-cisplatin combination with a different safety profile, as is the case for other cytotoxic drugs.
    Prescrire Int; 2009 Jun; 18(101):114. PubMed ID: 19637425
    [No Abstract]   [Full Text] [Related]  

  • 27. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T; Liu G; Tsao MS
    Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
    Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
    J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Personalized, targeted treatment of non-small cell lung cancer].
    Wolf J
    Dtsch Med Wochenschr; 2011 Mar; 136(10):480-5. PubMed ID: 21365525
    [No Abstract]   [Full Text] [Related]  

  • 30. Eve of the third millennium, providing an update on the management of non-small cell lung cancer (NSCLC).
    Le Chevalier T
    Anticancer Drugs; 2001 Jul; 12 Suppl 3():S1. PubMed ID: 11556248
    [No Abstract]   [Full Text] [Related]  

  • 31. [Advances in chemotherapy for lung cancer].
    Ono A; Yamamoto N
    Gan To Kagaku Ryoho; 2008 Sep; 35(9):1475-81. PubMed ID: 18799900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is there a role for maintenance therapy in non-small-cell lung cancer? An emerging issue.
    Petrelli F; Ghilardi M; Cremonesi M; Cabiddu M; Barni S
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1455-65. PubMed ID: 19828007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted therapies in non-small-cell lung cancer: a paradigm in evolution.
    Sangha R; Lara PN; Mack P; Gandara DR
    Clin Lung Cancer; 2008; 9 Suppl 3():S90-1. PubMed ID: 19419929
    [No Abstract]   [Full Text] [Related]  

  • 34. Updated clinical information on multitargeted antifolates in lung cancer.
    Scagliotti GV; Ceppi P; Capelletto E; Novello S
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S35-40. PubMed ID: 19362945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer.
    Gridelli C; Rossi A; Maione P; Rossi E; Castaldo V; Sacco PC; Colantuoni G
    Oncologist; 2009 Jun; 14(6):612-20. PubMed ID: 19474164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ixabepilone and the narrow path to developing new cytotoxic drugs.
    Gianni L
    J Clin Oncol; 2007 Aug; 25(23):3389-91. PubMed ID: 17606970
    [No Abstract]   [Full Text] [Related]  

  • 37. [Non-small cell lung cancer in the elderly. What chemotherapy?].
    Quoix E
    Rev Mal Respir; 2006 Nov; 23(5 Pt 3):16S95-16S99. PubMed ID: 17268344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer.
    Di Maio M; Chiodini P; Georgoulias V; Hatzidaki D; Takeda K; Wachters FM; Gebbia V; Smit EF; Morabito A; Gallo C; Perrone F; Gridelli C
    J Clin Oncol; 2009 Apr; 27(11):1836-43. PubMed ID: 19273711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells.
    Kodym E; Kodym R; Reis AE; Habib AA; Story MD; Saha D
    Lung Cancer; 2009 Oct; 66(1):37-47. PubMed ID: 19193471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted therapy of non-small-cell lung carcinoma.
    Tiwari D; Brodie SA; Brandes JC
    Ther Adv Respir Dis; 2012 Feb; 6(1):41-56. PubMed ID: 21730004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.